Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 mars 2026 07h00 HE | Source: Apellis Pharmaceuticals, Inc.

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company’s board of directors as of...
02 mars 2026 04h59 HE | Source: Mordor Intelligence

Antibiotics Market - 4.07% CAGR Forecast for 2026-2031 as Antimicrobial Innovation Strengthens Demand, Says Mordor Intelligence

Hyderabad, March 02, 2026 (GLOBE NEWSWIRE) -- According to Mordor Intelligence, the antibiotics market size was valued at USD 55.60 billion in 2025 and is projected to increase from USD 57.86...
02 mars 2026 04h04 HE | Source: Research and Markets

Monoclonal Antibodies (mAbs) for Oncology Global Report 2026: A $228 Billion Market by 2030, Driven by Technological Advances, New Product Launches, Label Expansions, Increasing Prevalence

Dublin, March 02, 2026 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies for Oncology: Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for monoclonal...
26 févr. 2026 13h35 HE | Source: PatentVest, Inc.

PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race

Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report, “The Oral Small-Molecule...
26 févr. 2026 07h00 HE | Source: Juvenescence

Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership

PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients with metabolic and fibrotic diseaseCarmel Nanthakumar,...
26 févr. 2026 06h31 HE | Source: Research and Markets

PD-L1 Biomarker Testing Market Research Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The "PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's...
25 févr. 2026 09h44 HE | Source: Research and Markets

Electronic Drug Delivery System Market - Global Forecast 2026-2032: Opportunities in Home-based Therapies, Innovative Tech, and Compliance Standards

Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The "Electronic Drug Delivery System Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The electronic...
25 févr. 2026 09h42 HE | Source: Research and Markets

$56.64 Bn Biomethane Market by Feedstock, Production Process, End-use, Region - Global Forecast to 2030: Market to Grow at a CAGR of 28%

Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The "Biomethane Market by Feedstock, Production Process, End-use, Region - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's...
24 févr. 2026 08h00 HE | Source: Artelo Biosciences

Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

SOLANA BEACH, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating...
24 févr. 2026 02h00 HE | Source: Avacta Group PLC

Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis

Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu® Clinical trial with AVA6103 is expected to be initiated...

Page précédente

Page suivante